Alto Neuroscience, Inc.
ANRO
$3.43
$0.020.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.72% | 0.21% | 9.43% | -4.70% | -19.48% |
| Total Depreciation and Amortization | -1.17% | 0.59% | 39.34% | 7.96% | 16.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.57% | 62.27% | -11.07% | -23.06% | 7.75% |
| Change in Net Operating Assets | 127.80% | -4,806.06% | -96.45% | 94.83% | 660.78% |
| Cash from Operations | 16.77% | -27.15% | -11.04% | -0.27% | -6.47% |
| Capital Expenditure | 100.00% | 95.26% | 49.65% | -195.59% | -51.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 95.26% | 49.65% | -195.59% | -51.79% |
| Total Debt Issued | -100.00% | 1,475.04% | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 304.08% | -26.87% | 9.84% | -99.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 212.27% | 56.32% | -200.00% | 523.73% | 90.26% |
| Cash from Financing | -93.28% | 18,526.53% | -96.28% | 662.82% | -100.17% |
| Foreign Exchange rate Adjustments | 86.36% | -466.67% | 185.71% | -40.00% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.17% | 44.51% | -17.96% | 6.94% | -109.95% |